Cheng Liang, Zhuang He, Yang Shuo, Jiang Huijie, Wang Song, Zhang Jun
College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Department of Radiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Front Genet. 2018 Dec 20;9:657. doi: 10.3389/fgene.2018.00657. eCollection 2018.
As a biomarker of inflammation, C-reactive protein (CRP) has attracted much attention due to its role in the incidence of type 2 diabetes mellitus (T2DM). Prospective studies have observed a positive correlation between the level of serum CRP and the incidence of T2DM. Recently, studies have reported that drugs for curing T2DM can also decrease the level of serum CRP. However, it is not yet clear whether high CRP levels cause T2DM. To evaluate this, we conducted a Mendelian randomization (MR) analysis using genetic variations as instrumental variables (IVs). Significantly associated single nucleotide polymorphisms (SNPs) of CRP were obtained from a genome-wide study and a replication study. Therein, 17,967 participants were utilized for the genome-wide association study (GWAS), and another 14,747 participants were utilized for the replication of identifying SNPs associated with CRP levels. The associations between SNPs and T2DM were from the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) consortium. After removing SNPs in linkage disequilibrium (LD) and T2DM-related SNPs, the four remaining CRP-related SNPs were deemed as IVs. To evaluate the pooled influence of these IVs on the risk of developing T2DM through CRP, the penalized robust inverse-variance weighted (IVW) method was carried out. The combined result (OR 1.114048; 95% CI 1.058656 to 1.172338; = 0.024) showed that high levels of CRP significantly increase the risk of T2DM. In the subsequent analysis of the relationship between CRP and type 1 diabetes mellitus (T1DM), the pooled result (OR 1.017145; 95% CI 0.9066489 to 1.14225; = 0.909) supported that CRP levels cannot determine the risk of developing T1DM.
作为一种炎症生物标志物,C反应蛋白(CRP)因其在2型糖尿病(T2DM)发病中的作用而备受关注。前瞻性研究观察到血清CRP水平与T2DM发病率之间存在正相关。最近,有研究报道治疗T2DM的药物也可降低血清CRP水平。然而,目前尚不清楚高CRP水平是否会导致T2DM。为评估这一点,我们使用基因变异作为工具变量(IVs)进行了孟德尔随机化(MR)分析。从全基因组研究和重复研究中获得了与CRP显著相关的单核苷酸多态性(SNPs)。其中,17967名参与者用于全基因组关联研究(GWAS),另外14747名参与者用于重复鉴定与CRP水平相关的SNPs。SNPs与T2DM之间的关联来自糖尿病遗传学复制与荟萃分析(DIAGRAM)联盟。在去除连锁不平衡(LD)中的SNPs和与T2DM相关的SNPs后,剩余的四个与CRP相关的SNPs被视为IVs。为评估这些IVs通过CRP对发生T2DM风险的综合影响,采用了惩罚稳健逆方差加权(IVW)方法。综合结果(比值比1.114048;95%置信区间1.058656至1.172338;P = 0.024)表明,高CRP水平显著增加T2DM风险。在随后对CRP与1型糖尿病(T1DM)关系的分析中,综合结果(比值比1.017145;95%置信区间0.9066489至1.14225;P = 0.909)支持CRP水平不能决定发生T1DM的风险。